WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has secured its fifth U.S. patent for QTORIN™ 3.9% rapamycin anhydrous gel, reinforcing its position in the development of treatments for rare skin diseases. The newly granted patent No. 12,268,673 extends patent protection for QTORIN™ rapamycin into 2038 and covers its composition and methods of use, including its application for microcystic lymphatic malformations (microcystic LMs).
QTORIN™ rapamycin holds the potential to become the first FDA-approved treatment for microcystic LMs, a serious and debilitating genetic condition affecting over 30,000 patients in the U.S. Characterized by leaking and bleeding malformed lymphatic vessels, the condition often leads to recurrent infections and significant complications. Currently, there are no approved therapies for this disease.
“This fifth U.S. patent reflects the significant innovation behind the development of QTORIN™ rapamycin and Palvella’s QTORIN™ platform,” said Wes Kaupinen, Founder and CEO of Palvella Therapeutics. “We are pleased to further strengthen our growing intellectual property portfolio as part of our pursuit to develop the first targeted therapy for microcystic lymphatic malformations.”
The gel has already received Breakthrough Therapy, Orphan Drug, and Fast Track Designations from the FDA, signaling its potential to fill a critical unmet need. If approved, it would also be eligible for seven years of market exclusivity under its Orphan Drug designation.
Palvella’s continued advancements in rare disease therapeutics underscore its commitment to addressing the needs of underserved patient populations, offering hope for those who currently have no viable treatment options.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.